Live Bending Spoons Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about

Lucid Diagnostics Inc.

LUCD

About Lucid Diagnostics Inc.

Lucid Diagnostics Inc. is a medical diagnostics company focused on early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease (GERD). Its key products, EsoGuard and EsoCheck, offer non-invasive testing solutions. With a $60 billion market opportunity, Lucid targets 30 million at-risk U.S. individuals. The company is expanding access through partnerships and direct-to-consumer initiatives, addressing a vital need in cancer prevention.

This description was generated via AI from an annual report. Updated almost 2 years ago.

Latest SEC Filings from Lucid Diagnostics Inc.

  1. 1
    1

    Lucid Diagnostics Reports 27% Revenue Growth but Faces Significant Losses in Q2 2026

    via official filing (AI summary) 2 months ago 0 comments
  2. 2
    1

    Lucid Diagnostics Reports 52% Revenue Growth to $1.3 Million in Q1 2026

    via official filing (AI summary) 5 months ago 0 comments
  3. 3
    1

    Lucid Diagnostics Reports $4.7 Million Revenue with Increased Losses in 2025

    via official filing (AI summary) 7 months ago 0 comments
  4. 4
    1

    Lucid Diagnostics Reports Q3 2025 Revenue Increase but Continued Operational Losses

    via official filing (AI summary) 11 months ago 0 comments
  5. 5
    1

    Lucid Diagnostics Reports $1.2 Million Revenue in Q2 2025, Net Loss of $7.9 Million

    via official filing (AI summary) about 1 year ago 0 comments
  6. 6
    1

    Lucid Diagnostics Reports 17.3% Revenue Decline and Increased Losses in Q1 2025

    via official filing (AI summary) over 1 year ago 0 comments
  7. 7
    1

    Lucid Diagnostics Reports $4.3 Million Revenue for Fiscal Year 2024, Faces $45.5 Million Net Loss

    via official filing (AI summary) over 1 year ago 0 comments
  8. 8
    1

    Lucid Diagnostics Reports Revenue Growth, Narrowing Losses in Q3 2024

    via official filing (AI summary) almost 2 years ago 0 comments
  9. 9
    1

    Lucid Diagnostics Reports Revenue Growth to $976,000, Operating Loss of $11.19 Million for Q2 2024

    via official filing (AI summary) about 2 years ago 0 comments
  10. 10
    1

    Lucid Diagnostics Reports 124% Revenue Increase to $1.0 Million in Q1 2024

    via official filing (AI summary) over 2 years ago 0 comments
  11. 11
    1

    Lucid Diagnostics Reports Revenue Growth to $783,000 Despite Continued Operating Losses

    via official filing (AI summary) almost 3 years ago 0 comments
  12. 12
    1

    Lucid Diagnostics Reports Q2 2023 Revenue of $159,000 and Net Loss of $11.4 Million

    via official filing (AI summary) about 3 years ago 0 comments
  13. 13
    1

    Lucid Diagnostics Reports Revenue Growth to $446,000 but Incurred $16.2 Million Net Loss in Q1 2023

    via official filing (AI summary) over 3 years ago 0 comments
  14. 14
    1

    Lucid Diagnostics Reports Significant Revenue Decline and Increased Losses in Q3 2022

    via official filing (AI summary) almost 4 years ago 0 comments
  15. 15
    1

    Lucid Diagnostics Reports $14.6 Million Net Loss in Q2 2022, Revenue Increases to $189,000

    via official filing (AI summary) about 4 years ago 0 comments
  16. 16
    1

    Lucid Diagnostics Reports $189,000 Revenue and $12.3 Million Net Loss for Q1 2022

    via official filing (AI summary) over 4 years ago 0 comments
  17. 17
    1

    Lucid Diagnostics Reports $200,000 Revenue in Q3 2021, Faces $6.96 Million Net Loss

    via official filing (AI summary) almost 5 years ago 0 comments